Angina gene therapy company XyloCor raises $17M series A round

Gene therapy company XyloCor Therapeutics Inc. (Philadelphia, Pa.) raised $17 million in a series A round led by Sofinnova Ventures and Life Science Partners.

XyloCor’s lead candidate is XC001, a gene therapy that stimulates the formation of new coronary blood vessels by delivering VEGF in a single myocardial injection. The company plans to start a Phase I trial of XC001 next year to treat refractory angina...